Completed PHASE1 INTERVENTIONAL 2-arm NCT02369861

Study of ST266 Eye Drops in Treating Dry Eye

A Randomized, Masked, Active Placebo-controlled Phase 1 Study of Amnion-derived Cellular Cytokine Solution (ACCS) Eye Drops in the Treatment of Dry Eye

Sponsor: Noveome Biotherapeutics, formerly Stemnion

Conditions Dry Eye Syndrome

Interventions Refresh Lubricant Eye Drops ST266

Updated 7 times since 2017 Last updated: May 9, 2019 Started: Mar 31, 2015 Primary completion: Oct 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02369861, this PHASE1 trial focuses on Dry Eye Syndrome and remains completed. Sponsored by Noveome Biotherapeutics, formerly Stemnion, it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jun 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Noveome Biotherapeutics, formerly Stemnion
U.S. Navy Bureau of Medicine

Data source: Noveome Biotherapeutics, formerly Stemnion

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States